Warmest thoughts and best wishes for a wonderful Christmas and a Happy New Year.Wishing you a Happy Holiday season from your friends at SunWay Biotech. Our office will only be closed for New Years Day from 31 December to 2 January and will get back to regular operation starting from 3 January. For emergencies during this period, please contact us by email. We will get back to you as soon as possible.

  President Tsai Ing-Wen met with representatives of the winning medical institutions and biomedical industry of the 26th “National Biotechnology Medical Quality Award” this morning. The President remarked that today’s awardees, coming from medical and biomedical sectors, have all dedicated their efforts towards the health of the public. She expressed her gratitude for everyone’s contributions and extended her congratulations to those who have received the “SNQ National Biotechnology Medical Quality Award,” a prize esteemed as the “Oscars of the Taiwan biomedical world.” Each awarded team and product holds a world-class standard, thus strengthening the competitiveness of Taiwan’s biomedical industry further. In the highly influential SNQ National Quality Mark competition, SunWay Biotech’s flagship product, ANKASCIN® 568-R red yeast rice extract, excelled among 260 competitors, winning the only bronze award in the Nutrition and Health Category – Special Functional Health Ingredient Group and even clinching first place in the category! This prestigious honor was accepted by General Manager Pan on behalf of SunWay Biotech, signifying the company’s exceptional innovation and quality in the health food sector, which has received high recognition from the government, industry, and academia. Source: Office of the President

The first clinical study, which has been published in the Journal of Food and Drug Analysis, documents that ANKASCIN® 568-R is effective in reducing subjects’ serum cholesterol and low-density lipoprotein cholesterol (LDL-C) to nearly desirable levels in as little as 4 weeks and were maintained in 8 weeks. Forty subjects (Inclusion criteria: LDL-C in the range of 130-190 mg/dL and serum cholesterol greater than 180 mg/dL) completed the double-blind, placebo-controlled randomized 12-week study. The administration group took 110 mg ANKASCIN® 568-R/one capsule/day for eight weeks. After four weeks of treatment (110 mg ANKASCIN® 568-R/day), the changes in the lipid levels showed that the active products had a more favorable effect than the placebo. Compared to the baseline, statistically significant decreases of 11.9% and 19.0% were observed in TC and LDL-C levels, respectively (p < 0.05 for all pairs). This study demonstrated that subjects administered 110 mg of ANKASCIN® 568-R for more than four weeks exhibited a significant reduction in serum TC and LDL-C levels. To assess the safety of this ingredient, scientists assayed aspartate transaminase (AST) and alanine aminotransferase (ALT) levels in the liver, and blood urea nitrogen (BUN), creatinine, and uric acid levels in the kidney. The results imply no significant effect on renal metabolism and physiological function. These results indicate that supplementation of ANKASCIN® 568-R reduces the risks of serum TC and […]